Vermont/Vermont Mun Bnd Bnk's Bonds Raised to 'AA+' and 'A+' Sep 00

  • ID: 2084473
  • September 2000
  • Region: Vermont
  • Standard & Poors
1 of 3


  • Vermont
  • Vermont Mun Bnd Bank
  • MORE

NEW YORK (Standard & Poor's CreditWire) Sept. 12, 2000--Standard & Poor's today raised its rating on Vermont's $515.4 million GO bonds to double-'A'-plus from double-'A'. The outlook is stable. In conjunction with this rating revision, Standard & Poor's also raised its underlying rating to single-'A'-plus from single-'A' on Vermont Municipal Bond Bank's bonds, issued for Vermont and itself, as follows: -- $365.49 million GO bonds, -- $64.46 million GO refunding bonds 1998 series 1 and 1998 series 2, -- $8.84 million refunding bonds series 1999A, -- $42.39 million GO bonds series 1991-1, and -- $48.55 million GO bonds 1 series 2000. Vermont's upgrade is based on: -- A strong capital planning focus that concentrates on utilizing current surpluses for capital...

Companies mentioned in this report are:
- Vermont
- Vermont Mun Bnd Bank

Action: Upgraded

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Vermont
- Vermont Mun Bnd Bank

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.